Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2002; 40:662-668
© 2002 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bonz, A. W.
Right arrow Articles by Voelker, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bonz, A. W.
Right arrow Articles by Voelker, W.

CLINICAL STUDY: ADJUNCTIVE THERAPY AND PCI

effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial)

Andreas W. Bonz, MD*,*, Björn Lengenfelder*, J.örg Strotmann, MD*, Stefanie Held, MD*, Oliver Turschner, MD*, Kerstin Harre, MD*, Christian Wacker, MD*, Christiane Waller, MD*, Nikolaus Kochsiek, MD*, Malte Meesmann, MD*, Ludwig Neyses, MD*, Peter Schanzenbächer, MD*, Georg Ertl, MD* and Wolfram Voelker, MD*

* Department of Cardiology, University of Würzburg, Würzburg, Germany

Manuscript received October 16, 2001; revised manuscript received April 16, 2002, accepted May 15, 2002.

* Reprint requests and correspondence: Dr. Andreas W. Bonz, Medizinische Universitätsklinik, Josef Schneider Strasse 2, 97080 Würzburg, Germany.
a.bonz{at}medizin.uni-wuerzburg.de

OBJECTIVES: The Troponin in Planned PTCA/Stent Implantation With or Without Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Tirofiban (TOPSTAR) trial investigated: 1) the amount of troponin T (TnT) release after nonacute, elective percutaneous coronary intervention (PCI) in patients pretreated with aspirin and clopidogrel; and 2) the effect of additional glycoprotein (GP) IIb/IIIa receptor inhibiton on postinterventional TnT release.

BACKGROUND: No data are available yet as to whether additional administration of a GP IIb/IIIa receptor antagonist might be beneficial in patients undergoing elective PCI already pretreated with aspirin and clopidogrel.

METHODS: After bolus application of the study medication (tirofiban [T] or placebo [P]), PCI was performed followed by an 18-h continuous infusion of T/P. Primary end point of the study was incidence and amount of TnT release after elective PCI after 24 h.

RESULTS: A total of 12 h after PCI troponin release was detected in 63% of the patients receiving P and in 40% of the patients receiving T (p < 0.05), after 24 h in 69% (P) and 48% (T) (p < 0.05) and after 48 h in 74% (P) versus 58% (T) (p < 0.08) of the patients. No differences were observed regarding major bleeding, intracranial bleeding or nonhemorrhagic strokes. After nine months a reduction of combined death/myocardial infarction/target vessel revascularization could be observed in the tirofiban group ([T] 2.3% vs. [P] 13.04%, p < 0.05).

CONCLUSIONS: Troponin T release occurs after successful intervention in 74% of the patients undergoing elective PCI after 48 h even after pretreatment with aspirin and clopidogrel. The GP IIb/IIIa receptor antagonist tirofiban is able to decrease the incidence of troponin release significantly in this patient population.

Abbreviations and Acronyms
  ACT
  activated clotting time
  CK
  creatine kinase
  GP
  glycoprotein
  MI
  myocardial infarction
  P
  placebo group
  PAU
  platelet aggregation units
  PCI
  percutaneous coronary intervention
  PTCA
  percutaneous transluminal coronary angioplasty
  RPFA
  rapid platelet function assay
  T
  tirofiban group
  TnT
  troponin T
  TOPSTAR
  Troponin in Elective PTCA/STent Implantation With or Without Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Tirofiban
  TVR
  target vessel revascularization




This article has been cited by other articles:


Home page
Eur Heart JHome page
M. Valgimigli, G. Biondi-Zoccai, M. Tebaldi, A. W.J. van 't Hof, G. Campo, C. Hamm, J. ten Berg, L. Bolognese, F. Saia, G. B. Danzi, et al.
Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials
Eur. Heart J., September 14, 2009; (2009) ehp376v1.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. Y. Fung, J. Saw, A. Starovoytov, C. Densem, P. Jokhi, S. J. Walsh, R. S. Fox, K. H. Humphries, E. Aymong, D. R. Ricci, et al.
Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial.
J. Am. Coll. Cardiol., March 10, 2009; 53(10): 837 - 845.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
T. Uetani, T. Amano, S. Kumagai, H. Ando, K. Yokoi, T. Yoshida, B. Kato, M. Kato, N. Marui, M. Nanki, et al.
Intracoronary Electrocardiogram Recording With a Bare-Wire System: Perioperative ST-Segment Elevation in the Intracoronary Electrocardiogram Is Associated With Myocardial Injury After Elective Coronary Stent Implantation
J. Am. Coll. Cardiol. Intv., February 1, 2009; 2(2): 127 - 135.
[Abstract] [Full Text] [PDF]


Home page
Arch SurgHome page
J. M. O'Riordan, R. J. Margey, G. Blake, and P. R. O'Connell
Antiplatelet Agents in the Perioperative Period
Arch Surg, January 1, 2009; 144(1): 69 - 76.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. Jaffe, T. Charron, G. Puley, A. Dick, and B. H. Strauss
Microvascular Obstruction and the No-Reflow Phenomenon After Percutaneous Coronary Intervention
Circulation, June 17, 2008; 117(24): 3152 - 3156.
[Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
D. J. Kereiakes and P. A. Gurbel
Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention
J. Am. Coll. Cardiol. Intv., April 1, 2008; 1(2): 111 - 121.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
O. F. Bertrand, R. De Larochelliere, J. Rodes-Cabau, G. Proulx, O. Gleeton, C. Manh Nguyen, J.-P. Dery, G. Barbeau, B. Noel, E. Larose, et al.
A Randomized Study Comparing Same-Day Home Discharge and Abciximab Bolus Only to Overnight Hospitalization and Abciximab Bolus and Infusion After Transradial Coronary Stent Implantation
Circulation, December 12, 2006; 114(24): 2636 - 2643.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
M. E. Bertrand and E. Van Belle
Triple antiplatelet treatment in patients presenting with non-ST-segment elevation acute coronary syndromes
Eur. Heart J. Suppl., October 1, 2006; 8(suppl_G): G59 - G63.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
W. L. Miller, K. N. Garratt, M. F. Burritt, R. J. Lennon, G. S. Reeder, and A. S. Jaffe
Baseline troponin level: key to understanding the importance of post-PCI troponin elevations
Eur. Heart J., May 1, 2006; 27(9): 1061 - 1069.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
J. Herrmann
Peri-procedural myocardial injury: 2005 update
Eur. Heart J., December 1, 2005; 26(23): 2493 - 2519.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. P. Giugliano and E. Braunwald
The Year in Non--ST-Segment Elevation Acute Coronary Syndromes
J. Am. Coll. Cardiol., September 6, 2005; 46(5): 906 - 919.
[Full Text] [PDF]


Home page
Eur Heart JHome page
M. J. Claeys, M. G. Van der Planken, J. M. Bosmans, J. J. Michiels, F. Vertessen, P. Van Der Goten, F. L. Wuyts, and C. J. Vrints
Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis
Eur. Heart J., March 2, 2005; 26(6): 567 - 575.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. Valgimigli, G. Percoco, D. Barbieri, F. Ferrari, G. Guardigli, G. Parrinello, O. Soukhomovskaia, and R. Ferrari
The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: The advance trial
J. Am. Coll. Cardiol., July 7, 2004; 44(1): 14 - 19.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. Dalby, G. Montalescot, C. B. d. Sollier, E. Vicaut, T. Soulat, J.-P. Collet, R. Choussat, V. Gallois, G. Drobinski, L. Drouet, et al.
Eptifibatide provides additional platelet inhibition in Non-ST-Elevation myocardial infarction patients already treated with aspirin and clopidogrel: Results of the platelet activity extinction in Non-Q-Wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study
J. Am. Coll. Cardiol., January 21, 2004; 43(2): 162 - 168.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
W. L. Miller, K. N. Garratt, M. F. Burritt, G. S. Reeder, and A. S. Jaffe
Timing of Peak Troponin T and Creatine Kinase-MB Elevations After Percutaneous Coronary Intervention
Chest, January 1, 2004; 125(1): 275 - 280.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
C. P. Cannon and A. G.G. Turpie
Unstable Angina and Non-ST-Elevation Myocardial Infarction: Initial Antithrombotic Therapy and Early Invasive Strategy
Circulation, June 3, 2003; 107(21): 2640 - 2645.
[Full Text] [PDF]


Home page
JAMAHome page
S. R. Steinhubl, P. B. Berger, J. T. Mann III, E. T. A. Fry, A. DeLago, C. Wilmer, E. J. Topol, and for the CREDO Investigators
Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention: A Randomized Controlled Trial
JAMA, November 20, 2002; 288(19): 2411 - 2420.
[Abstract] [Full Text] [PDF]


Home page
Journal Watch CardiologyHome page
Troponin T Release After Elective PCI
Journal Watch Cardiology, November 1, 2002; 2002(1101): 3 - 3.
[Full Text]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement